• 25378 Citations
  • 77 h-Index
1969 …2019

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Allan Lipton is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 7 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer

Willumsen, N., Ali, S. M., Leitzel, K., Drabick, J. J., Yee, N., Polimera, H. V., Nagabhairu, V., Krecko, L., Ali, A., Maddukuri, A., Moku, P., Ali, A., Poulose, J., Menon, H., Pancholy, N., Costa, L., Karsdal, M. A. & Lipton, A., Dec 1 2019, In : Scientific reports. 9, 1, 19761.

Research output: Contribution to journalArticle

Open Access
  • 3 Scopus citations

    High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts

    Lipton, A., Leitzel, K., Ali, S. M., Polimera, H. V., Nagabhairu, V., Marks, E., Richardson, A. E., Krecko, L., Ali, A., Koestler, W., Esteva, F. J., Leeming, D. J., Karsdal, M. A. & Willumsen, N., Dec 1 2018, In : International Journal of Cancer. 143, 11, p. 3027-3034 8 p.

    Research output: Contribution to journalArticle

  • 11 Scopus citations

    The C-Terminal Intact Forms of Periostin (iPTN) Are Surrogate Markers for Osteolytic Lesions in Experimental Breast Cancer Bone Metastasis

    Gineyts, E., Bonnet, N., Bertholon, C., Millet, M., Pagnon-Minot, A., Borel, O., Geraci, S., Bonnelye, E., Croset, M., Suhail, A., Truica, C., Lamparella, N., Leitzel, K., Hartmann, D., Chapurlat, R., Lipton, A., Garnero, P., Ferrari, S., Clézardin, P. & Rousseau, J. C., Nov 1 2018, In : Calcified Tissue International. 103, 5, p. 567-580 14 p.

    Research output: Contribution to journalArticle

  • 5 Scopus citations

    Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: The OPTIMIZE-2 randomized clinical trial

    Hortobagyi, G. N., Van Poznak, C., Harker, W. G., Gradishar, W. J., Chew, H., Dakhil, S. R., Haley, B. B., Sauter, N., Mohanlal, R., Zheng, M. & Lipton, A., Jul 2017, In : JAMA Oncology. 3, 7, p. 906-912 7 p.

    Research output: Contribution to journalArticle

  • 61 Scopus citations

    Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab)

    Ho, D., Huang, J., Chapman, J. A. W., Leitzel, K., Ali, S. M., Shepherd, L., Parulekar, W. R., Ellis, C. E., Crescnzo, R. J., Zhu, L., Virk, S., Nomikos, D., Aparicio, S., Gelmon, K. A., Carney, W. P. & Lipton, A., Aug 1 2017, In : Breast Cancer Research and Treatment. 164, 3, p. 571-580 10 p.

    Research output: Contribution to journalArticle

  • 4 Scopus citations